Time to develop high blood pressure while taking Lenvatinib

Hypertension (HTN) is the most common adverse event during treatment with lenvatinib, but data on its optimal treatment are limited. It is more prominent in subjects over 75 years old. In a phase III select trial of radioactive iodine-refractory thyroid cancer, the median onset of new or worsening hypertension was 16 days in the select group and 26 days in the response group. Patients in the treatment group also reported fistula formation, leading to tumor bleeding. Adverse reactions arising from treatment should be managed supportively, with dose adjustment and treatment discontinuation if necessary.

High blood pressure is the most reported side effect, and routine blood pressure checks are recommended. Poorly controlled hypertension has been reported to lead to serious complications. Early detection may be possible through 24-hour blood pressure monitoring while taking lenvatinib. Before initiating treatment, patients with underlying hypertension should have their blood pressure controlled and maintained within a stable range. Lenvatinib should be discontinued in patients whose elevated blood pressure is not controlled while receiving optimal blood pressure therapy.

Lenvatinib The original drug has been launched in China and has entered the scope of Class B medical insurance. The price of 4mg*30 tablets per box may be more than 3,000 yuan. Lenvatinib original drug currently on the market overseas, specifications 4mg*30 capsules, may cost more than 1,000 yuan per box (the price may fluctuate due to exchange rates). Lenvatinib generic drugs are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of a box of 4mg*30 tablets produced by a Bangladesh pharmaceutical factory may be RMB 800 (the price may fluctuate due to exchange rates).